These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29703677)

  • 1. Concomitant CALR and LNK mutations leading to essential thrombocythemia with erythrocytosis.
    Luque Paz D; Boyer F; Beucher A; Bouvier A; Jouanneau-Courville R; Guardiola P; Lambert D; Delneste Y; Hunault M; Blanchet O; Ugo V
    Blood Cells Mol Dis; 2018 Jul; 71():75-76. PubMed ID: 29703677
    [No Abstract]   [Full Text] [Related]  

  • 2. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
    Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
    PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Who to screen for calreticulin mutations? An audit of real-life practice and review of current evidence.
    Haslam K; Langabeer SE
    Eur J Intern Med; 2017 May; 40():e22-e23. PubMed ID: 28132789
    [No Abstract]   [Full Text] [Related]  

  • 4. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.
    Rotunno G; Mannarelli C; Guglielmelli P; Pacilli A; Pancrazzi A; Pieri L; Fanelli T; Bosi A; Vannucchi AM;
    Blood; 2014 Mar; 123(10):1552-5. PubMed ID: 24371211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis.
    Spolverini A; Pieri L; Guglielmelli P; Pancrazzi A; Fanelli T; Paoli C; Bosi A; Nichele I; Ruggeri M; Vannucchi AM
    Haematologica; 2013 Sep; 98(9):e101-2. PubMed ID: 23812944
    [No Abstract]   [Full Text] [Related]  

  • 7. Somatic mutations of calreticulin in myeloproliferative neoplasms.
    Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
    N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia.
    Kang MG; Choi HW; Lee JH; Choi YJ; Choi HJ; Shin JH; Suh SP; Szardenings M; Kim HR; Shin MG
    Oncotarget; 2016 Aug; 7(35):57036-57049. PubMed ID: 27486987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LNK mutations and myeloproliferative disorders.
    McMullin MF; Cario H
    Am J Hematol; 2016 Feb; 91(2):248-51. PubMed ID: 26660394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible new LNK mutations in myeloproliferative neoplasms.
    Ha JS; Jeon DS
    Am J Hematol; 2011 Oct; 86(10):866-8. PubMed ID: 21922527
    [No Abstract]   [Full Text] [Related]  

  • 11. Essential Thrombocythemia Associated With Germline JAK2 G571S Variant and Somatic CALR Type 1 Mutation.
    Panovska-Stavridis I; Eftimov A; Ivanovski M; Pivkova-Veljanovska A; Cevreska L; Hermouet S; Dimovski AJ
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):e55-7. PubMed ID: 27009537
    [No Abstract]   [Full Text] [Related]  

  • 12. Presence of calreticulin mutations in JAK2-negative polycythemia vera.
    Broséus J; Park JH; Carillo S; Hermouet S; Girodon F
    Blood; 2014 Dec; 124(26):3964-6. PubMed ID: 25305205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calreticulin mutation does not contribute to disease progression in essential thrombocythemia by inhibiting phagocytosis.
    Daitoku S; Takenaka K; Yamauchi T; Yurino A; Jinnouchi F; Nunomura T; Eto T; Kamimura T; Higuchi M; Harada N; Saito N; Miyamoto T; Iwasaki H; Akashi K
    Exp Hematol; 2016 Sep; 44(9):817-825.e3. PubMed ID: 27185380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diversities of Calreticulin Gene Mutations in Macedonian Patients With Essential Thrombocythemia.
    Panovska-Stavridis I; Eftimov A; Ivanovski M; Stojanovic A; Georgievski B; Cevreska L; Dimovski AJ
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):477-81. PubMed ID: 27521277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study.
    Pérez Encinas MM; Sobas M; Gómez-Casares MT; Abuin Blanco A; Noya Pereira MS; Raya JM; Andrade-Campos MM; Álvarez Larrán A; Lewandowski K; Łukasz S; Hernández Boluda JC; Ferrer-Marín F; Fox ML; Gołos A; Gasior Kabat M; Magro Mazo E; Czyż A; Martín Martín A; Bellosillo Paricio B; Quinteiro García C; González Martín JM; Stuckey R
    Eur J Haematol; 2021 Mar; 106(3):371-379. PubMed ID: 33275803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased B cell activation is present in JAK2V617F-mutated, CALR-mutated and triple-negative essential thrombocythemia.
    Lim KH; Chen CG; Chang YC; Chiang YH; Kao CW; Wang WT; Chang CY; Huang L; Lin CS; Cheng CC; Cheng HI; Su NW; Lin J; Chang YF; Chang MC; Hsieh RK; Lin HC; Kuo YY
    Oncotarget; 2017 May; 8(20):32476-32491. PubMed ID: 28415571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LNK mutations in JAK2 mutation-negative erythrocytosis.
    Lasho TL; Pardanani A; Tefferi A
    N Engl J Med; 2010 Sep; 363(12):1189-90. PubMed ID: 20843259
    [No Abstract]   [Full Text] [Related]  

  • 18. CALR versus JAK2 mutated essential thrombocythaemia - a report on 141 patients.
    Trifa AP; Popp RA; Cucuianu A; Bănescu C; Tevet M; Martin B; Murat M; Vesa SC; Dima D; Cândea M; Militaru MS; Pop IV
    Br J Haematol; 2015 Jan; 168(1):151-3. PubMed ID: 25103987
    [No Abstract]   [Full Text] [Related]  

  • 19. Two faces of ET: CALR and JAK2.
    Chao MP; Gotlib J
    Blood; 2014 Mar; 123(10):1438-40. PubMed ID: 24627549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.
    Mejía-Ochoa M; Acevedo Toro PA; Cardona-Arias JA
    BMC Cancer; 2019 Jun; 19(1):590. PubMed ID: 31208359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.